Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.62 |
| ▸ | PDE5A | O76074 | 17/20 | 0.52 |
| ▸ | GUCY1A1 | Q02108 | 2/20 | 0.51 |
| ▸ | GUCY1B1 | Q02153 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29424226 | 1.00 | ADORA3 (0.62) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL7509551 | 0.91 | ADORA3 (0.55) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL255819 | 0.89 | ADORA3 (0.78) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL10083045 | 0.88 | KCNH2 (0.79) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL20278520 | 0.88 | ADORA3 (0.66) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL29105173 | 0.85 | ADORA3 (0.62) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL28491103 | 0.85 | ADORA3 (0.54) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL173886 | 0.82 | ADORA3 (0.64) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL255860 | 0.82 | KCNH2 (0.64) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL19399351 | 0.82 | ADORA3 (0.57) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180169095-A1 | THE USE OF SGC STIMULATORS, SGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF DIGITAL ULCERS (DU) CONCOMITANT TO SYSTEMIC SCLEROSIS (SSC) | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-06-21 | — | — | US | claimed |
| EP-3291811-A1 | THE USE OF SGC STIMULATORS, SGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF DIGITAL ULCERS (DU) CONCOMITANT TO SYSTEMIC SCLEROSIS (SSC) | Bayer Pharma Aktiengesellschaft (DE) | 2018-03-14 | — | — | EP | claimed |
| WO-2016177660-A1 | THE USE OF SGC STIMULATORS, SGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF DIGITAL ULCERS (DU) CONCOMITANT TO SYSTEMIC SCLEROSIS (SSC) | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-11-10 | — | — | WO | claimed |
| US-9266885-B2 | Substituted 5-fluoro-1H-pyrazolopyridines and their use | ADVERIO PHARMA GMBH (DE) | 2016-02-23 | — | — | US | claimed |
| EP-2576547-B1 | SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND USE THEREOF | ADVERIO PHARMA GMBH (DE) | 2016-01-27 | — | — | EP | claimed |
| US-20150080414-A1 | SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-03-19 | — | — | US | claimed |
| US-8921377-B2 | Substituted 5-fluoro-1H-pyrazolopyridines and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-12-30 | — | — | US | claimed |
| US-20120022084-A1 | Substituted 5-fluoro-1H-pyrazolopyridines and their use | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-26 | — | — | US | claimed |
| US-20220409618-A1 | SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND THEIR USE | ADVERIO PHARMA GMBH (DE) | 2022-12-29 | — | — | US | disclosed |
| US-20220023246-A1 | STIMULATORS AND/OR ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE (SGC) IN COMBINATION WITH AN INHIBITOR OF NEUTRAL ENDOPEPTIDASE (NEP INHIBITOR) AND/OR AN ANGIOTENSIN AII ANTAGONIST AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-01-27 | — | — | US | disclosed |
| US-11166932-B2 | Stimulators and/or activators of soluble guanylate cyclase (sGC) in combination with an inhibitor of neutral endopeptidase (NEP inhibitor) and/or an angiotensin AII antagonist and the use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-11-09 | — | — | US | disclosed |
| EP-3787610-A1 | THE USE OF SGC ACTIVATORS AND SGC STIMULATORS FOR THE TREATMENT OF COGNITIVE IMPAIRMENT | Bayer Aktiengesellschaft (DE) | 2021-03-10 | — | — | EP | disclosed |
| US-20210052528-A1 | THE USE OF SGC ACTIVATORS AND SGC STIMULATORS FOR THE TREATMENT OF COGNITIVE IMPAIRMENT | BAYER AKTIENGESELLSCHAFT (DE) | 2021-02-25 | — | — | US | disclosed |
| US-20200397785-A1 | SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND THEIR USE | ADVERIO PHARMA GMBH (DE) | 2020-12-24 | — | — | US | disclosed |
| US-20120022084-A1 | Substituted 5-fluoro-1H-pyrazolopyridines and their use | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-26 | — | — | US | disclosed |
| WO-2011161099-A1 | USE OF STIMULATORS AND ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE FOR TREATING SICKLE-CELL ANEMIA AND CONSERVING BLOOD SUBSTITUTES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-29 | — | — | WO | disclosed |
| WO-2011161099-A1 | USE OF STIMULATORS AND ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE FOR TREATING SICKLE-CELL ANEMIA AND CONSERVING BLOOD SUBSTITUTES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-29 | — | — | WO | disclosed |
| WO-2011147809-A1 | SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011147810-A1 | THE USE OF sGC STIMULATORS, sGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF SYSTEMIC SCLEROSIS (SSc). | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011147810-A1 | THE USE OF sGC STIMULATORS, sGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF SYSTEMIC SCLEROSIS (SSc). | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180169095-A1 | THE USE OF SGC STIMULATORS, SGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF DIGITAL ULCERS (DU) CONCOMITANT TO SYSTEMIC SCLEROSIS (SSC) | PDE5A, PDE2A, PDE3A | ADORA3 3072/4885KCNH2 2945/4885PDE5A 1/4885 |
| US-20150080414-A1 | SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND THEIR USE | PFKP, PON1, FABP3 | ADORA3 1633/4885KCNH2 128/4885PDE5A 121/4885 |
| US-20200397785-A1 | SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND THEIR USE | PFKP, PON1, FABP3 | ADORA3 1633/4885KCNH2 128/4885PDE5A 121/4885 |
| US-20210052528-A1 | THE USE OF SGC ACTIVATORS AND SGC STIMULATORS FOR THE TREATMENT OF COGNITIVE IMPAIRMENT | GUCY1A2, GUCY1A1, PRKG1 | ADORA3 1349/4885KCNH2 2540/4885PDE5A 10/4885 |
| US-11166932-B2 | Stimulators and/or activators of soluble guanylate cyclase (sGC) in combination with an inhibitor of neutral endopeptidase (NEP inhibitor) and/or an angiotensin AII antagonist and the use thereof | MME, ECE1, REN | ADORA3 2019/4885KCNH2 3014/4885PDE5A 28/4885 |
| US-20220409618-A1 | SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND THEIR USE | PFKP, PON1, FABP3 | ADORA3 1633/4885KCNH2 128/4885PDE5A 121/4885 |
| US-20220023246-A1 | STIMULATORS AND/OR ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE (SGC) IN COMBINATION WITH AN INHIBITOR OF NEUTRAL ENDOPEPTIDASE (NEP INHIBITOR) AND/OR AN ANGIOTENSIN AII ANTAGONIST AND THE USE THEREOF | MME, ECE1, REN | ADORA3 2019/4885KCNH2 3014/4885PDE5A 28/4885 |
| US-20120022084-A1 | Substituted 5-fluoro-1H-pyrazolopyridines and their use | PFKP, PON1, FABP3 | ADORA3 1633/4885KCNH2 128/4885PDE5A 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.